Latest News & Features
Americas
The patent system in the US and the EU is not rewarding complex research into treatments for a host of prevalent diseases and conditions, and reforms are going in the wrong direction, says Erika Lietzan of the University of Missouri School of Law. 12 July 2017
Big Pharma
Precision medicine has come a long way since the completion of the Human Genome Project in 2003, but how have IP regimes developed in this area, asks Sheena Linehan of Potter Clarkson. 12 July 2017
Big Pharma
The Italian Patent and Trademark Office’s Board of Appeal has ruled that there are no rules preventing the office from adjudicating requests to limit the term of supplementary protection certificates. 12 July 2017
Biotechnology
The European Patent Office has reopened cases in which the decision depends entirely on the patentability of plants or animals obtained by an essentially biological process. 11 July 2017
Americas
The Broad Institute of MIT and Harvard has announced that it has entered talks to create a worldwide licensing pool for CRISPR/Cas9 patents. 11 July 2017
article
With the two-year Brexit negotiations underway, life sciences companies and their lawyers will be watching closely to see how their businesses and IP will be affected. LSIPR reports with views from the UK, France and Germany. 10 July 2017
Sectors
With legal developments in the CRISPR field ramping up this year, LSIPR examines the current international landscape and the options for parties interested in using the gene-editing technology. 9 July 2017
Big Pharma
The products made by GQ Life Sciences, based in Boston, make IP-related sequence searching easier for scientists, patent searchers and practitioners, as senior product manager Ellen Sherin tells LSIPR. 8 July 2017
Big Pharma
The UK Supreme Court has ruled that Actavis’s generic versions of cancer drug Alimta directly infringe patents owned by Eli Lilly, reversing two earlier decisions. 7 July 2017
Europe
Biotech company Silence Therapeutics has filed a case on supplementary protection certificates at the English Patents Court against Alnylam and The Medicines Company. 7 July 2017